Efficacy of anticancer agents in vitro and in vivo using cultured human endometrial carcinoma cells--study of therapeutic index.
Employing the new cell line, NUE-1, which was derived from cells of ascites in a woman with endometrial carcinoma, the sensitivity test for anticancer agents was carried out in culture and xenografts in nude mice. Anticancer activity in vitro was evaluated by counting surviving cells, and the therapeutic index was expressed by LD50 for mice/MLD90 in vitro. NUE-1 cells were inoculated subcutaneously in BALB/c nude mice, and then tumors serially transplanted were used as materials. Anticancer agents (ADM, CDDP, CHA3, CQ, MMC) at 1/3 LD50 dosage for mice were administered intraperitoneally on a schedule of 3 doses for every 4 days. The results were as follows: The therapeutic index of ADM was highest at five to nineteen times the others In vivo, ADM demonstrated + activity, whereas others had no significant effect There was a close correlation between the therapeutic index and in vivo anticancer effect using nude mice.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002460:Cell Line; D002945:Cisplatin / Q000494:pharmacology; D003114:Colony-Forming Units Assay; D004317:Doxorubicin / Q000494:pharmacology; D005260:Female; D007928:Lethal Dose 50; D051379:Mice; D008819:Mice, Nude; D016685:Mitomycin; D008937:Mitomycins / Q000494:pharmacology; D014410:Tumor Stem Cell Assay; D014594:Uterine Neoplasms / Q000473:pathology*
D000970:Antineoplastic Agents; D008937:Mitomycins; D016685:Mitomycin; D004317:Doxorubicin; D002945:Cisplatin